摘要
目的 了解多药耐药相关类蛋白P 糖蛋白 (P gp)、谷胱甘肽 S 转移酶 π(GST π)、DNA拓扑异构酶 Ⅱα(Topo Ⅱα)在乳腺癌化疗耐药机制中的作用及相互间关系。方法 用免疫组化S P法对 91例未经抗肿瘤治疗的原发性乳腺癌和 18例术后经化疗复治乳腺癌组织检测P gp、GST π、Topo Ⅱα蛋白表达。结果 (1)P gp在原发性乳腺癌中阳性表达率为 40 %,术后经化疗复治乳腺癌中阳性表达率为 6 1%。两组P gp表达率差异有显著性 (P <0 0 5 )。 (2 )GST π和P gp在乳腺癌组织表达正相关 (P <0 0 5 )。 (3)原发性乳腺癌Topo Ⅱα表达水平与一些提示预后差的临床病理特征明显相关 (P <0 0 5 )。术后经化疗复治乳腺癌中阳性表达率为 17%,与原发癌相比显著降低 (P <0 0 5 )。结论 乳腺癌耐药是多因素参与的复杂过程 ,P gp、GST π、TopoⅡα均参与其化疗耐药性形成。化疗后的复治乳腺癌比初治原发癌具有更普遍的耐药性。TopoⅡα水平可作为评价乳腺癌恶性度的指标。
Purpose To investigate the role of expression of MDR1/P-glycoprotein(P-gp), topoisomerase Ⅱα(Topo Ⅱα) and glutathione-S-transferase-π(GST-π) in chemotherapeutic resistance of breast cancer and their interrelationships. Methods By using immunohistochemical S-P method,the expressions of P-gp, Topo Ⅱα and GST-π were determined in 91 cases of untreated primary breast cancer and 18 cases of relapsed or metastatic breast cancer after chemotherapy. Results (1)Positive expressions of P-gp were 40% in 91 cases of untreated primary breast cancer and 61% in 18 cases of relapsed or metastatic breast cancer respectively,and the difference was statistically significant(P<0.05). (2)Positive correlation existed between the expression of P-gp and GST-π(P<0.05). (3)Expression of Topo Ⅱα was significantly related to some clinicopathological features. Positive expressions of Topo Ⅱα were 17% in 18 cases of relapsed or metastatic breast cancer, and the difference was statistically significant in comparison to that in untreated primary breast cancer. Conclusions The results provide an evidence that chemoresistance is intrinsic to the breast cancer and seems to be a multifactorial process. The retreated breast cancer is more extensively resistant than untreated primary breast cancer. The expression of topo Ⅱα is related to poor prognosis in untreated primary breast cancer.
出处
《临床与实验病理学杂志》
CAS
CSCD
2003年第3期266-269,共4页
Chinese Journal of Clinical and Experimental Pathology
基金
安徽医科大学校基金资助 (No 2 0 112 )
关键词
乳腺癌
癌组织
多药耐药性
蛋白基因
基因表达
化疗
breast neoplasms
durg resistance, multidrug
P-glycoprotein
glutathione-S-transferase-π
topoisomerase Ⅱ
